- Home
- RCUS vs KEN Comparison
RCUS vs KEN Comparison
Compare RCUS & KEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | KEN |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | RCUS | KEN |
|---|---|---|
| Price | $25.41 | $61.45 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.88 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 10.3K |
| Earning Date | 10-28-2025 | 12-03-2025 |
| Dividend Yield | N/A | ★ 7.88% |
| EPS Growth | N/A | ★ 177.70 |
| EPS | N/A | ★ 8.96 |
| Revenue | $240,000,000.00 | ★ $803,304,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.69 |
| Revenue Growth | N/A | ★ 8.15 |
| 52 Week Low | $6.50 | $27.10 |
| 52 Week High | $26.40 | $62.88 |
Technical Indicators
Market Signals| Indicator | RCUS | KEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.57 | 66.95 |
| Support Level | $24.32 | $60.63 |
| Resistance Level | $26.40 | $62.88 |
| Average True Range (ATR) | 1.30 | 1.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 82.78 | 77.14 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include OPC Power Plants, CPV Group, and ZIM. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.